This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Sarma, R. J. Articles by Bach, J. R. Search for Related Content PubMed Articles by Sarma, R. J. Articles by Bach, J. R. Social Bookmarking                         What's this?

Cardiovascular Considerations in the Management of Duchenne Muscular Dystrophy

Associate Professor of Clinical Medicine, University of Southern California; Director of Cardiology, Rancho Los Amigos Medical Center

Charles A. Stewart

Clinical Associate Professor of Radiology, University of California-Los Angeles, Nuclear Medicine, Rancho Los Amigos Medical Center

Irene S. Gilgoff

Clinical Associate Professor of Pediatrics, University of Southern California; Chairman of Pediatrics, Rancho Los Amigos Medical Center

John R. Bach

Associate Professor of Physical Medicine and Rehabilitation; Vice Chairman, Department of Physical Medicine and Rehabilitation, UNDNJ-New Jersey Medical School, Newark, NJ

Cardiac disease is second only to pulmonary complications as the leading cause of death for patients with progressive neuromuscular disease. The extent of cardiomyopathy in patients with myopathic disease correlates poorly with the extent of skeletal or respiratory muscle weakness. Until recently, little was done to evaluate and treat this problem. However, resting gated radionuclide ventriculography (RNV or MUGA) is a reliable method for determining left ventricular function and wall motion and is more reliable than M-mode echocardiography for the measurement of left ventricular ejection fraction (LVEF) in these patients. The reliable determination of ventricular function permits closer monitoring of cardiomyopathic progression and the results of treatment. We report preliminary success in using captopril, an angiotensin converting enzyme (ACE) inhibitor, and hydralazine, a cardiac afterload reducing agent, in improving LVEFs and, therefore, cardiac function for some patients with myopathic cardiomyopathy. Until specific therapy is available, treatment must be guided by patient response to the therapeutic modalities used for cardiac patients in general.

Key Words: Duchenne muscular dystrophy • Cardiomyopathy • Neuromuscular disease.

Neurorehabilitation and Neural Repair, Vol. 6, No. 2, 113-119 (1992)
DOI: 10.1177/136140969200600208


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?